Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.77 [0.67, 0.89] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 0.60 [0.54, 0.67] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.92 [1.59, 2.33] | | > 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.49 [0.15, 1.65] | | < 1 | | 0% | 1 study (1/-) | 87.3 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.14 [0.86, 1.52] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.10 [0.60, 2.03] | | < 1 | | 0% | 1 study (1/-) | 37.5 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 1.46 [1.07, 1.99] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.40 [1.05, 1.87] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.43 [1.02, 2.00] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.81 [0.43, 1.53] | | < 1 | | 0% | 1 study (1/-) | 74.4 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 1.38 [1.04, 1.83] | | < 1 | | 0% | 1 study (1/-) | 1.2 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.23 [0.50, 3.01] | | < 1 | | 0% | 1 study (1/-) | 32.4 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 1.00 [0.06, 16.09] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 1.00 [0.02, 50.65] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 1.05 [0.58, 1.89] | | < 1 | | 0% | 1 study (1/-) | 43.7 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.75 [0.17, 3.37] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.45 [0.15, 1.30] | | < 1 | | 0% | 1 study (1/-) | 92.9 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 2.53 [0.49, 13.10] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 1.00 [0.02, 50.65] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 1.00 [0.02, 50.65] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 5.64 [1.24, 25.63] | | < 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
Epistaxis TRAE (grade 3-4) | 8.09 [0.43, 153.59] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.31 [0.57, 3.03] | | < 1 | | 0% | 1 study (1/-) | 26.2 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 1.48 [0.85, 2.57] | | < 1 | | 0% | 1 study (1/-) | 8.2 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 8.09 [0.43, 153.59] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
Hypertension TRAE (grade 3-4) | 1.00 [0.57, 1.78] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 1.77 [0.51, 6.09] | | < 1 | | 0% | 1 study (1/-) | 18.4 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 2.01 [0.18, 22.26] | | < 1 | | 0% | 1 study (1/-) | 28.6 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.91 [0.80, 4.57] | | < 1 | | 0% | 1 study (1/-) | 7.2 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 1.27 [0.83, 1.94] | | < 1 | | 0% | 1 study (1/-) | 13.8 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 4.03 [0.18, 89.56] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.50 [0.02, 14.97] | | < 1 | | 0% | 1 study (1/-) | 65.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.23 [0.50, 3.01] | | < 1 | | 0% | 1 study (1/-) | 32.4 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 3.04 [0.61, 15.15] | | < 1 | | 0% | 1 study (1/-) | 8.8 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 10.14 [0.55, 186.27] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
Sepsis TRAE (grade 3-4) | 2.01 [0.07, 60.02] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 4.04 [0.45, 36.32] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.94 [0.47, 1.89] | | < 1 | | 0% | 1 study (1/-) | 56.8 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 1.21 [0.37, 3.99] | | < 1 | | 0% | 1 study (1/-) | 37.9 % | NA | not evaluable | | non important | - |